Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis
BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis
Sponsor: University Hospital, Ghent
A PHASE2 clinical study on Colorectal Neoplasms, this trial is completed. The trial is conducted by University Hospital, Ghent and has accumulated 12 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Jan 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Feb 2021 — Jan 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Jan 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Ghent
For direct contact, visit the study record on ClinicalTrials.gov .